Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

European Journal of Cancer

Volumn 34, Issue 8, 1998, Pages 1274-1281

  Miwa, M ^a   Ura, M ^a   Nishida, M ^a   Sawada, N ^a   Ishikawa, T ^a   Mori, K ^a   Shimma, N ^a   Umeda, I ^a   Ishitsuka, H ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

5' deoxy 5 fluorocytidine; 5' deoxy 5 fluorouridine; Carboxylesterase; Cytidine deaminase; Thymidine phosphorylase

Indexed keywords

5 CHLOROURACIL DERIVATIVE; CAPECITABINE; CARBAMIC ACID DERIVATIVE; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; UFT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GRAFT; COLON CANCER; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; CARBOXYLIC ESTER HYDROLASES; CYTIDINE DEAMINASE; DEOXYCYTIDINE; FEMALE; FLOXURIDINE; FLUOROURACIL; HUMANS; LIVER; MALE; MICE; NEOPLASMS; THYMIDINE PHOSPHORYLASE;

EID: 0032127244     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00058-6     Document Type: Article

References (21)

1. 1. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980, 71, 112-123.
2. 2. Suzuki S, Hongu Y, Fukazawa H, Ichihara S, Shimizu H. Tissue distribution of 5′-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. Gann 1980, 71, 238-245.
3. 3. Miwa M, Eda H, Fukuda H, Fujimoto K, Ishitsuka H. Comparative studies on the antitumor activity of fluorinated pyrimidines, 5′-DFUR, Tegafur, UFT and FUra, with various murine tumors. Jpn J Cancer Chemother 1988, 15, 1755-1763.
4. 4. Uehara N, Baba H, Nitta K, et al. The therapeutic effect of orally administered 5′-deoxy-5-fluorouridine, 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors. Gann 1985, 76, 1034-1041.
5. 5. Taguchi T, Terasawa T, Abe O, Yoshida Y, Tominaga T, Ogawa N. A comparative study between 5′-DFUR and Tegafur in recurrent breast cancer. Jpn J Cancer Chemother 1985, 12, 2052-2060.
6. 6. Ninomiya Y, Miwa M, Eda H, et al. Comparative antitumor activity and intestinal toxicity of 5′-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5′-deoxy-5-fluorocytidine. Jpn Cancer Res 1990, 81, 188-195.
7. 7. Krenitsky TA, Mellors JW, Barclay RK. Pyrimidine nucleosidases. Their classification and relation to uric acid ribonucleoside phosphorylase. J Biol Chem 1965, 240, 1281-1286.
8. 8. Woodman PW, Sarrif AM, Heiderberger C. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2′-deoxycytidine. Cancer Res 1980, 40, 507-511.
9. 9. Arasaki M, Ishitsuka H, Kuruma I, et al. European Patent no. 92121538.0, 1992.
10. 10. Schroeder EF. 5-Halo-6-amino-uracils and derivatives thereof. U.S. Patent no. 2,731,465, 1956.
11. 11. Lowry OH, Rosebrough NJ, Farr A, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193, 265-275.
12. 12. Mosmann TJ. Rapid colorimetric assay for cellular and survival: application to proliferation and cytotoxicity assays. Immunol Meth 1985, 65, 55-63.
13. 13. Tahara H, Odagiri H, Ishikawa T, Kuruma I. Pharmacokinetics of fluoropyrimidine derivative (Ro 09-1978) in monkey. Proc Jpn Cancer Assoc (53rd Annual meeting), 2409, 1994.
14. 14. Bajetta E, Carnaghi C, Somma L, Stapino CG. A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori 1996, 82, 450-452.
15. 3. Biochim Biophys Acta 1996, 1312, 99-104.
16. 16. Kono H, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 1983, 31, 175-178.
17. 17. Furukawa T, Yoshimura A, Sumizawa T, et al. Angiogenic factor. Nature 1996, 356, 668.
18. 18. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platlet-derived endotherial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 1995, 64, 79-82.
19. 19. Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996, 88, 1107-1110.
20. 20. Ho DHW. Distribution of kinase and deaminase of 1-β-D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973, 33, 2816-2820.
21. 21. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998, 58, 685-690.